{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-120819","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2023-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.661312+00:00","generated_at":"2026-06-07T22:21:03.902978+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gain Therapeutics prices $9.4M public offering and concurrent private placement of common stock and warrants","bullets":["Public offering of 2,213,044 shares and 1,106,522 warrants at $2.005/unit; warrants exercisable at $2.75 for 5 years.","Concurrent private placement for $5.0M: common/pre-funded warrants and warrants for 2,500,088 shares at $2.00.","Aggregate gross proceeds $9.4M; net proceeds expected ~$8.35M after fees.","Proceeds to fund GT-02287 development for GBA1 Parkinson's and general corporate purposes.","Newbridge Securities sole underwriter; closing expected Nov 24, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-120819","json":"https://secwatch.observer/filing/0001104659-23-120819.json","markdown":"https://secwatch.observer/filing/0001104659-23-120819.md","text":"https://secwatch.observer/filing/0001104659-23-120819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465923120819/0001104659-23-120819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465923120819/tm2330139d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:21:03.902978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07cd61ab1ace2824a134a127bc43f0b3b558be66","claim":"Gain Therapeutics, Inc. entered into Underwriting Agreement with Newbridge Securities Corporation valued at aggregate gross proceeds of $4.4 million (effective 2023-11-21).","evidence_excerpt":"On November 21, 2023, Gain Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Newbridge Securities Corporation, as the underwriter named therein (the “ Underwriter ”), relating to the offering, issuance and sale of an aggregate of (i) 2,213,044 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”) and (ii) warrants to purchase 1,106,522 shares of Common Stock (the “ Warrants ” and the shares of Common Stock underlying the Warrants, the “ Warrant Shares ”) for aggregate gross proceeds of $4.4 million (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465923120819/0001104659-23-120819-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Newbridge Securities Corporation"},{"label":"Value","value":"aggregate gross proceeds of $4.4 million"},{"label":"Effective","value":"2023-11-21"}],"fact_type":"material_agreement"},{"claim_id":"e3224c56df01ba9a77090d34ba9100b74306cd07","claim":"Gain Therapeutics, Inc. entered into Securities Purchase Agreement with an accredited investor valued at aggregate gross proceeds of $5.0 million (effective 2023-11-21).","evidence_excerpt":"On November 21, 2023, in a private placement (the “ Concurrent Private Offering ”) to be completed concurrently with the completion of the Offering, the Company entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor (“ Private Purchaser ”) whereby the Company will issue an aggregate of (i) 744,026 shares of Common Stock (the “ Private Shares ”), (ii) pre-funded warrants (the “ Pre-Funded Warrants ”) exercisable for an aggregate of up to 1,756,062 shares of Common Stock and (iii) warrants (the “ Private Warrants ”) to purchase up to an aggregate of 2,500,088 shares of the Company’s common stock (“ Private Warrant Shares ”) for aggregate gross proceeds of $5.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465923120819/0001104659-23-120819-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"aggregate gross proceeds of $5.0 million"},{"label":"Effective","value":"2023-11-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}